Literature DB >> 15794383

Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study.

J Versijpt1, J C Debruyne, K J Van Laere, F De Vos, J Keppens, K Strijckmans, E Achten, G Slegers, R A Dierckx, J Korf, J L De Reuck.   

Abstract

OBJECTIVE: The objectives of the present study were to assess brain atrophy in multiple sclerosis (MS) patients during different disease stages and to investigate by PET and [11C]PK11195, a marker of microglial activation, the relationship between inflammation, atrophy and clinically relevant measures.
METHODS: Eight healthy subjects and 22 MS patients were included. Semiquantitative [11C]PK11195 uptake values, with normalization on cortical grey matter, were measured for magnetic resonance imaging T2- and T1-lesions and normal appearing white matter (NAWM). As atrophy index we used the ratio of the amount of white and grey matter divided by the ventricular size, using an optimized a priori based segmentation algorithm (SPM99).
RESULTS: Atrophy was significantly greater in MS patients compared to age-matched controls. A significant correlation was found between brain atrophy and both disease duration and disability, as measured with the Expanded Disability Status Scale. For NAWM, [11C]PK11195 uptake increased with the amount of atrophy, while T2-lesional [11C]PK11195 uptake values decreased according to increasing brain atrophy.
CONCLUSIONS: The present study suggests that brain atrophy, correlating with disease duration and disability, is directly related to NAWM and T2-lesional inflammation as measured by microglial activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794383     DOI: 10.1191/1352458505ms1140oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  53 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Decreased microglial activation in MS patients treated with glatiramer acetate.

Authors:  John N Ratchford; Christopher J Endres; Dima A Hammoud; Martin G Pomper; Navid Shiee; John McGready; Dzung L Pham; Peter A Calabresi
Journal:  J Neurol       Date:  2011-12-09       Impact factor: 4.849

Review 3.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

4.  Translocator protein 18 kDa negatively regulates inflammation in microglia.

Authors:  Keun-Ryung Bae; Hyun-Jung Shim; Deebika Balu; Sang Ryong Kim; Seong-Woon Yu
Journal:  J Neuroimmune Pharmacol       Date:  2014-04-01       Impact factor: 4.147

5.  Translocator protein PET imaging for glial activation in multiple sclerosis.

Authors:  Unsong Oh; Masahiro Fujita; Vasiliki N Ikonomidou; Iordanis E Evangelou; Eiji Matsuura; Erin Harberts; Yota Fujimura; Nancy D Richert; Joan Ohayon; Victor W Pike; Yi Zhang; Sami S Zoghbi; Robert B Innis; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-09-25       Impact factor: 4.147

Review 6.  Imaging microglial activation during neuroinflammation and Alzheimer's disease.

Authors:  Sriram Venneti; Clayton A Wiley; Julia Kofler
Journal:  J Neuroimmune Pharmacol       Date:  2008-12-04       Impact factor: 4.147

7.  The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders.

Authors:  Sriram Venneti; Guoji Wang; Jason Nguyen; Clayton A Wiley
Journal:  J Neuropathol Exp Neurol       Date:  2008-10       Impact factor: 3.685

Review 8.  In vivo imaging of neuroinflammation in schizophrenia.

Authors:  Ofer Pasternak; Marek Kubicki; Martha E Shenton
Journal:  Schizophr Res       Date:  2015-06-03       Impact factor: 4.939

Review 9.  Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy.

Authors:  Thomas Tourdias; Vincent Dousset
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

10.  [11C]-DPA-713 and [18F]-DPA-714 as new PET tracers for TSPO: a comparison with [11C]-(R)-PK11195 in a rat model of herpes encephalitis.

Authors:  Janine Doorduin; Hans C Klein; Rudi A Dierckx; Michelle James; Michael Kassiou; Erik F J de Vries
Journal:  Mol Imaging Biol       Date:  2009-03-28       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.